首页--医药、卫生论文--药学论文--药理学论文

基于普朗尼克F127的IL-1Ra热敏凝胶缓释制剂及其对糖尿病的药效学研究

Acknowledgements第8-9页
Table of Contents第9-14页
List of figures第14-16页
List of tables第16-17页
Abstract第17-19页
中文摘要第20-25页
PartⅠ: Study background and review of literature第25-111页
    Chapter 1 Type 2 diabetes mellitus and its treatment strategy第26-53页
        Abstract第27页
        1.1 Introduction第27-30页
        1.2 Mechanisms of inflammatory responses for pathogenesis of T2DM第30-33页
            1.2.1 Reduced oxygenation第31-32页
            1.2.2 Transcriptional pathways第32-33页
        1.3 Role of pro-inflammatory mediators for dissemination of T2DM第33-37页
            1.3.1 Cytokines第33-36页
                1.3.1.1 IL-1β第34-35页
                1.3.1.2 TNF-α第35页
                1.3.1.3 IL-6第35-36页
            1.3.2 Adipocytokines第36页
            1.3.3 Chemokines第36-37页
        1.4 Factors that potentiate tissue-specific inflammation in T2DM第37-39页
            1.4.1 Hyoerglvcemia第37页
            1.4.2 Dyslipidemia第37-38页
            1.4.3 Oxidative stress第38-39页
        1.5 Treatment strategies for T2DM第39-42页
            1.5.1 Diet-based therapy for treatment of T2DM第40-41页
            1.5.2 Use of anti-inflammatory agents for treatment of T2DM第41-42页
        1.6 Recent advances for treatment of T2DM and implications of IL-1Ra第42-44页
            1.6.1 Problems in delivery of IL-1Ra第43-44页
        1.7 Conclusion第44页
        References第44-53页
    Chapter 2 GK-rats: a non-obese spontaneous type 2 diabetic animal model第53-71页
        Abstract第54页
        2.1 Introduction第54-55页
        2.2 Animal-modelling for T2DM investigation第55-56页
        2.3 GK-rats第56-66页
            2.3.1 Changes in pre-diabetic period lead to overt diabetes in adult GK-rats第57-58页
            2.3.2 Mechanism of β-cell dysfunction第58页
            2.3.3 Mechanism of β-cell death第58-59页
            2.3.4 Development of T2DM第59页
            2.3.5 Activation of transcriptional pathways第59-60页
            2.3.6 Increased production of pro-inflammatory cytokines and chemokines第60-61页
            2.3.7 Mechanism of IL-1β production第61页
            2.3.8 Mechanism of hyperglycemia第61页
            2.3.9 Mechanism of dyslipidemia第61-62页
            2.3.10 Mechanism of Insulin resistance第62页
            2.3.11 Mechanism of intra-islet inflammation第62-63页
            2.3.12 Inflammation in peripheral tissues第63页
            2.3.13 Development of diabetic nephropathy第63-64页
            2.3.14 Therapeutic outcomes of anti-diabetic agents investigated on GK-rats第64-66页
        2.4 Conclusion第66页
        References第66-71页
    Chapter 3 IL-1Ra and its delivery strategies第71-111页
        Abstract第72页
        3.1 Introduction第72-73页
        3.2 Development of therapeutic proteins第73-74页
        3.3 Current delivery strategies for IL-1Ra第74-95页
            3.3.1 Fusion of IL-1Ra with different fusion protein and peptide partners第75-83页
                3.3.1.1 Fusion of IL-1Ra with elastin-like polypeptides (ELP)第75-78页
                3.3.1.2 Fusion of IL-1Ra with human serum albumin (HSA)第78-79页
                3.3.1.3 Fusion of IL-1Ra with albumin domain antibodies (AlbudAbs)第79-81页
                3.3.1.4 Mucosal delivery of IL-1Ra by sporulating recombinant bacteria第81-83页
            3.3.2 Polymeric-based delivery of IL-1Ra using biocompatible polymers第83-95页
                3.3.2.1 Development of lL-1Ra-loaded PLGA microspheres第84-86页
                3.3.2.2 Development of PEGylated IL-1Ra第86-87页
                3.3.2.3 Development of IL-1Ra-loaded complex coacervation thermo-reversible gel第87-88页
                3.3.2.4 Development of IL-1Ra-loaded self-assembled nanoparticles第88-89页
                3.3.2.5 Development of IL-1Ra-loadeddextran microparticles第89-90页
                3.3.2.6 Development of IL-1Ra loaded PF127-basedthermosensitive gel第90-95页
        3.4 Future perspectives第95-99页
        3.5 Conclusion第99页
        References第99-111页
PartⅡ: Experimental work第111-213页
    Chapter 4 Sequence comparison, structure similarity and computational docking of human IL-1Ra and ratIL-1Ra on rat receptor第112-125页
        Abstract第113页
        4.1 Introduction第113-114页
        4.2 Materials and Methods第114-116页
            4.2.1 Comparative modeling of protein sequences第114-115页
            4.2.2 3D protein structural modeling第115页
            4.2.3 Verification of 3D structural protein model第115页
            4.2.4 Protein structure refinement第115页
            4.2.5 Molecular visualization of protein structural similarity第115-116页
            4.2.6 Protein docking第116页
        4.3 Results第116-122页
            4.3.1 Pairwise sequence alignment of IL-1Ra_human and IL-1Ra_rat第116-117页
            4.3.2 Validation of protein structure models第117-118页
            4.3.3 Computer modeling of protein structure第118-119页
            4.3.4 Protein Structure refinement第119-120页
            4.3.5 Molecular visualization of protein structural similarity第120-121页
            4.3.6 Protein docking第121-122页
        4.5 Discussion第122-123页
        4.6 Conclusion第123页
        References第123-125页
    Chapter 5 IL-1Ra improves normoglycemia and insulin sensitivity in diabetic GK-rats第125-145页
        Abstract第126页
        5.1 Introduction第126-128页
        5.2 Materials and methods第128-130页
            5.2.1 Materials第128页
            5.2.2 Animals第128-129页
            5.2.3 In vivo treatment of IL-1Ra第129页
            5.2.4 Insulin sensitivity test (ITT)第129页
            5.2.5 Intraperitoneal glucose tolerance test (IPGTT)第129-130页
            5.2.6 Determination of insulin sensitivity and β-cell secretory function第130页
            5.2.7 Biochemical analysis第130页
            5.2.8 Immunohistochemistry第130页
            5.2.9 Statistical analysis第130页
        5.3 Results第130-137页
            5.3.1 IL-1Ra has no effects on weight gain and/or food intake in GK-rats第130-131页
            5.3.2 IL-1Ra improves normoglycemia in GK-rats第131-132页
            5.3.3 IL-1Ra improves insulin sensitivity in GK-rats第132-133页
            5.3.4 IL-1Ra improves glucose tolerance in GK-rats第133-134页
            5.3.5 Insulin sensitivity and β-cell secretory function determinations第134-135页
            5.3.6 IL-lRa improves metabolic parameters第135-136页
            5.3.7 Immunohistochemical analysis of CD68 in pancreatic islets第136-137页
            5.3.8 Adverse events第137页
        5.4 Discussion第137-142页
        5.5 Conclusion第142页
        References第142-145页
    Chapter 6 Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs itstherapeutic potentials第145-168页
        Abstract第146页
        6.1 Introduction第146-148页
        6.2 Materials and methods第148-152页
            6.2.1 Materials第148页
            6.2.2 Preparation of different concentrations of PF127第148页
            6.2.3 Determinations of gelation temperature, gelling rate and viscosity第148-149页
            6.2.4 In vitro release of IL-1Ra from PF127 gels第149页
            6.2.5 In vitro erosion profile of PF127 gel第149页
            6.2.6 Drug release kinetic study第149-150页
            6.2.7 In vivo study on Wistar-rats第150-151页
            6.2.8 Pharmacokinetic analysis of IL-1Ra第151页
            6.2.9 Bioactivity of IL-1Ra第151-152页
            6.2.10 In vitro-in vivo correlations (IVIVC) analysis第152页
            6.2.11 Statistical analysis第152页
        6.3 Results and discussion第152-164页
            6.3.1 Effect of concentrations of PF127 on GT,gelling rate and viscosity第152-153页
            6.3.2 In-vitro release of IL-1Ra第153-155页
            6.3.3 Drug release kinetic study第155-157页
            6.3.4 Correlation between in-vitro gel dissolution versus in-vitro drug release第157页
            6.3.5 Stability of IL-1Ra in gel formulation第157-158页
            6.3.6 Changes in serum levels of IL-1Ra第158-159页
            6.3.7 Determination of Pharmacolkinetic parameters of IL-1Ra第159-160页
            6.3.8 Changes in serum levels of IL-1Ra第160-162页
            6.3.9 In-vivo bioactivity of 1L-1Ra released from PF127 gel第162-163页
            6.3.10 In-vitro-in-vivo correlation(IVIVC)第163-164页
        6.4 Conclusion第164页
        References第164-168页
    Chapter 7 Stability studies of IL-1Ra loaded in PF127 gel during the stability-study period第168-184页
        Abstract第169页
        7.1 Introduction第169-171页
        7.2 Materials and Methods第171-174页
            7.2.1 Materials第171页
            7.2.2 PF127 formulation preparation第171页
            7.2.3 Effect of IL-1Ra on rheological behavior of PF127第171-172页
            7.2.4 In vitro release of IL-1Ra from PF127 gel第172页
            7.2.5 Determination of percent content of 1L-1Ra loaded in PF127 gel第172页
            7.2.6 DSC analysis of 1L-1Ra loaded in PF127 gel第172-173页
            7.2.7 FTIR analysis of IL-1Ra loaded in PF127 gel第173页
            7.2.8 SDS-PAGE analysis of IL-1Ra loaded in PF127 gel第173页
            7.2.9 Statistical analysis第173-174页
        7.3 Results第174-178页
            7.3.1 Effect of IL-1Ra on rheological behavior of PF127第174页
            7.3.2 In vitro release of IL-1Ra from PF127 gel第174-176页
            7.3.3 Determination of percent content of IL-1Ra loaded in PF127 gel第176页
            7.3.4 DSC analysis of IL-1Ra loaded in PF127 gel第176-177页
            7.3.5 FTIR analysis of IL-1Ra loaded in PF127 gel第177页
            7.3.6 SDS-PAGE analysis of IL-1Ra loaded in PF127 gel第177-178页
        7.4 Discussion第178-180页
        7.5 Conclusion第180-181页
        References第181-184页
    Chapter 8 Sustained delivery of IL-1Ra from PF127-based thermosensitive gel reduces hypergycemia indiabetic GK-rats第184-209页
        Abstract第185页
        8.1 Introduction第185-187页
        8.2 Materials and methods第187-190页
            8.2.1 Animals第187-188页
            8.2.2 Preparation of 25% PF127 gel and in vivo treatment of 1L-1Ra第188页
            8.2.3 Intraperitoneal glucose tolerance test(IPGTT)第188页
            8.2.4 Insulin sensitivity determinations第188-189页
            8.2.5 Biochemical analysis第189页
            8.2.6 Urine analysis第189页
            8.2.7 Immunohistochemistry第189-190页
            8.2.8 Histochemical analyses第190页
            8.2.9 Statistical analysis第190页
        8.3 Results第190-199页
            8.3.1 IL-1Ra reduces the extent of hyperglycemia in GK-rats第190-191页
            8.3.2 IL-1Ra loaded in PF127 gel improves glucose tolerance in GK-rats第191-193页
            8.3.3 Insulin sensitivity determinations第193-194页
            8.3.4 Effect of IL-1Ra loaded in PF127 gel on metabolic parameters第194-196页
            8.3.5 Effect of IL-1Ra and PF127 on Iddney function of GK-rats第196-197页
            8.3.6 Immunohistochemical analysis of CD68 in pancreatic islets第197页
            8.3.7 Histopathological inspection of skin sections第197-198页
            8.3.8 Histopathological inspection of kidney sections第198-199页
            8.3.9 Adverse events第199页
        8.4 Discussion第199-204页
        8.5 Conclusion第204页
        References第204-209页
    Chapter9 Key findings and Future Perspectives第209-213页
        9.1 Key findings第210-211页
        9.2 Future perspectives第211-213页
Author biography第213-218页
    Author introduction第213页
    Honors and awards第213页
    List of Publications第213页
    Publications from dissertation第213-215页
    Other publications第215-218页

论文共218页,点击 下载论文
上一篇:紫外光对煤表面氧化的影响研究
下一篇:阳离子捕收剂对煤系高岭岩的浮选规律研究